Back to News
Market Impact: 0.4
Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Tyra Biosciences priced a $400 million underwritten offering of common stock and pre-funded warrants. The financing materially strengthens the clinical-stage biotech's cash resources but is likely dilutive to existing shareholders, creating near-term pressure on the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
TYRA-0.45
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns
- Microsoft's Big Bets on AI Start to Pay Off